Clinical Trials Browser

Active not recruiting × Interventional × anlotinib × Clear all

NCT05685550 2026-02-05

Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study

Phase 2 Active not recruiting

Progression Free Survival(PFS)

NCT07142421 2025-08-26

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

Phase 2 Active not recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04165330 2025-02-24

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Phase 1/2 Active not recruiting

SarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Sarcoma, Small Cell Lung Carcinoma

NCT05400070 2024-10-18

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Phase 2 Active not recruiting

Lung Neoplasms

NCT04523272 2024-10-15

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Phase 3 Active not recruiting

Advanced Renal Cancer

NCT04891900 2024-07-08

TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

Phase NA Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT05816499 2024-06-17

AK104IIT018

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung